Rare diseases
Investigational molecules
Locations
Study of Daratumumab Injections for Patients with Moderate to Severe Chronic Fatigue Syndrome
NorwayStudy of iberdomide alone or with drug combinations for patients with multiple myeloma: testing safety and effectiveness of different doses
FranceStudy Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
BelgiumStudy on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
DenmarkStudy of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma
BelgiumStudy Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant
CzechiaStudy of Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone for Patients with Newly Diagnosed AL Amyloidosis with Heart Involvement
FranceLong-term Safety Study of Daratumumab with Drug Combination for Patients with Multiple Myeloma or Smoldering Multiple Myeloma
BelgiumStudy on Carfilzomib, Lenalidomide, and Dexamethasone for Patients Under 70 with High-Risk Smoldering Multiple Myeloma
SpainStudy on Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma Patients Not Eligible for Transplant
GermanyStudy on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
